Abstract
AbstractAttention-deficit/hyperactivity disorder (ADHD) has been associated with increased risk for physical comorbidity. This study used a twin cohort to investigate the association between physical diseases and phenotypic variations of ADHD. A twin cohort enriched for ADHD and other neurodevelopmental conditions were analysed. The Attention Problems subscale of the Child Behavior Checklist/Adult Behavior Checklist (CBCL/ABCL-AP) was used to measure the participants’ severity of ADHD symptoms. Physical health issues were obtained with a validated questionnaire and were tested in relation to ADHD symptom severity in a co-twin control model. Neurological problems were significantly associated with a diagnosis of ADHD. A conditional model for the analysis of within-twin pair effects revealed an inverse association between digestive problems and the severity of ADHD symptoms, after adjusting for co-existing autism spectrum disorder and ADHD medications. Our findings suggest that individuals with ADHD are susceptible to neurological problems, why a thorough neurological check-up is indicated in clinical practice for this population. In addition, health conditions of digestive system could be considered as a non-shared environmental factor for behavioral phenotypes in ADHD. It supports the possible role of gut-brain axis in the underpinnings of ADHD symptoms, at least for a subgroup of individuals with certain genetic predisposition.
Funder
the Swedish Research Council
Vinnova
Formas
FORTE
the Swedish Brain foundation
Stockholm Brain Institute
Autism and Asperger Association Stockholm
Queen Silvia Jubilee Fund
Solstickan Foundation
PRIMA Child and Adult Psychiatry
the Pediatric Research Foundation at Astrid Lindgren Children’s Hospital
Sällskapet Barnavård
the Swedish Foundation for Strategic Research
Jerring Foundation
the Swedish Order of Freemasons
Kempe- Carlgrenska Foundation
Sunnderdahls Handikappsfond
The Jeansson Foundation
EU-AIMS
the Innovative Medicines Initiative Joint Undertaking
the European Union’s Seventh Framework Programme
the European Federation of Pharmaceutical Industries and Associations companies’ in-kind contributions
Autism Speaks
EU AIMS-2-TRIALS
Karolinska Institute
Publisher
Springer Science and Business Media LLC